Table 8

Most common adverse events (reported by ≥10% of patients), total and by dose at onset of AE, safety population (n = 60)

Number (%) of patients


Dose at onset

Preferred term

Total

10 mg

20 mg

30, 35 mg

40, 45 mg

50 mg


Headache

21 (35.0)

10 (16.7)

6 (10.0)

5 (8.3)

1 (1.7)

3 (5.0)

Nausea

15 (25.0)

6 (10.0)

3 (5.0)

3 (5.0)

2 (3.3)

2 (3.3)

Diarrhoea

15 (25.0)

6 (10.0)

3 (5.0)

3 (5.0)

2 (3.3)

5 (8.3)

Nasopharyngitis

15 (25.0)

5 (8.3)

2 (3.3)

6 (10.0)

1 (1.7)

2 (3.3)

Hyperhidrosis

12 (20.0)

3 (5.0)

3 (5.0)

4 (6.7)

1 (1.7)

1 (1.7)

Upper respiratory tract infection

12 (20.0)

2 (3.3)

5 (8.3)

3 (5.0)

2 (3.3)

2 (3.3)

Fatigue

10 (16.7)

3 (5.0)

1 (1.7)

2 (3.3)

5 (8.3)

0 (0)

Dizziness

10 (16.7)

3 (5.0)

2 (3.3)

4 (6.7)

0 (0)

1 (1.7)

Vomiting

8 (13.3)

3 (5.0)

1 (1.7)

4 (6.7)

0 (0)

2 (3.3)

Abnormal dreams

6 (10.0)

2 (3.3)

0 (0)

3 (5.0)

1 (1.7)

1 (1.7)

Arthralgia

6 (10.0)

0 (0)

3 (5.0)

0 (0)

3 (5.0)

0 (0)

Back pain

6 (10.0)

0 (0)

2 (3.3)

2 (3.3)

1 (1.7)

1 (1.7)

Influenza like illness

6 (10.0)

1 (1.7)

1 (1.7)

1 (1.7)

1 (1.7)

3 (5.0)

Influenza

6 (10.0)

0 (0)

2 (3.3)

1 (1.7)

0 (0)

3 (5.0)

Lethargy

6 (10.0)

2 (3.3)

2 (3.3)

0 (0)

2 (3.3)

0 (0)

Oropharyngeal pain

6 (10.0)

0 (0)

2 (3.3)

2 (3.3)

1 (1.7)

1 (1.7)

Pain in extremity

6 (10.0)

0 (0)

2 (3.3)

3 (5.0)

2 (3.3)

0 (0)

Rash

6 (10.0)

2 (3.3)

2 (3.3)

0 (0)

1 (1.7)

2 (3.3)


Wade et al. BMC Psychiatry 2011 11:42   doi:10.1186/1471-244X-11-42

Open Data